<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00046904</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000257027</org_study_id>
    <secondary_id>NCCTG-N00C1</secondary_id>
    <secondary_id>NCI-P02-0232</secondary_id>
    <secondary_id>MC00C8</secondary_id>
    <secondary_id>1497-00</secondary_id>
    <nct_id>NCT00046904</nct_id>
  </id_info>
  <brief_title>Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer</brief_title>
  <official_title>Phase III Placebo-Controlled, Randomized, Double-Blind Comparison Of Etanercept (Enbrel) Versus Placebo For The Treatment Of Cancer-Associated Weight Loss And Anorexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Etanercept is a substance that is being studied as a treatment for cachexia&#xD;
      (weight loss) and anorexia (lack of appetite) in patients who have cancer. It is not yet&#xD;
      known whether etanercept is effective in improving cancer-related cachexia and anorexia.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of etanercept in treating&#xD;
      cancer-related cachexia and anorexia in patients who have advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare etanercept vs placebo in the treatment of cancer-related cachexia and anorexia,&#xD;
           in terms of weight measurement and rate of weight change, in patients with advanced&#xD;
           malignancies.&#xD;
&#xD;
        -  Determine the effect of this drug on nausea and vomiting in these patients.&#xD;
&#xD;
        -  Assess the functional status and appetite of patients treated with this drug.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this drug.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine whether this drug prolongs survival of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to primary malignant disease (lung vs gastrointestinal vs other),&#xD;
      severity of weight loss (less than 4.6 kg vs at least 4.6 kg), planned concurrent&#xD;
      chemotherapy (yes vs no), age (less than 50 vs 50 and over), gender, planned use of megestrol&#xD;
      or other progestational agent (yes vs no), and GBU Prognostic Index (good vs bad vs unsure).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive etanercept subcutaneously (SC) twice weekly.&#xD;
&#xD;
        -  Arm II: Patients receive placebo SC twice weekly. Treatment in both arms continues for a&#xD;
           maximum of 24 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, weekly for 1 month, and then monthly during&#xD;
      treatment.&#xD;
&#xD;
      Patients are followed every 6 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 274 patients (137 per treatment arm) will be accrued for this&#xD;
      study within 19 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of weight gain and rate of weight change</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in appetite</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life (QOL) as assessed by the QOL UNISCALE and the Functional Assessment of Cancer Therapy-Anorexia/cachexia (FACT-An) scale at baseline, weekly for one month, and then monthly during study treatment</measure>
  </secondary_outcome>
  <condition>Anorexia</condition>
  <condition>Cachexia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy except brain cancer&#xD;
&#xD;
               -  If the patient has multiple primaries or an unknown primary, the currently active&#xD;
                  cancer cannot be brain cancer&#xD;
&#xD;
          -  Disease considered incurable with available therapies&#xD;
&#xD;
          -  No clinical evidence of ascites&#xD;
&#xD;
          -  Weight loss of at least 5 pounds (2.3 kg) within the past 2 months (excluding&#xD;
             perioperative weight loss) and/or estimated caloric intake of less than 20 cal/kg&#xD;
             daily&#xD;
&#xD;
          -  Weight gain determined by physician to be beneficial&#xD;
&#xD;
          -  Patient perceives weight loss as a problem&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No poorly controlled congestive heart failure&#xD;
&#xD;
          -  No poorly controlled hypertension&#xD;
&#xD;
          -  No pacemaker, implanted defibrillator, stents, or metal suture material in the heart&#xD;
             or great vessels (for patients participating in the BIA translational portion of the&#xD;
             study)&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No known mechanical obstruction of the alimentary tract&#xD;
&#xD;
          -  No malabsorption&#xD;
&#xD;
          -  No intractable vomiting (more than 5 episodes/week)&#xD;
&#xD;
          -  Not concurrently receiving tube feedings or parenteral nutrition&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Able to reliably administer subcutaneous medication twice weekly&#xD;
&#xD;
          -  Alert and mentally competent&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 1 month since prior infliximab&#xD;
&#xD;
          -  No concurrent live vaccination&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Concurrent chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 month since prior adrenal steroids&#xD;
&#xD;
          -  No concurrent adrenal steroids (inhalant, topical, or optical steroids allowed)&#xD;
&#xD;
               -  Concurrent short-term dexamethasone for chemotherapy-induced emesis is allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Concurrent radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior etanercept&#xD;
&#xD;
          -  No concurrent evaluation with another device that injects an electrical current into&#xD;
             the body (for patients participating in the bioelectrical impendance analysis [BIA]&#xD;
             translational portion of the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MBCCOP - Gulf Coast</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology Associates at June E. Nylen Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center at Medcenter One Hospital</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Geisinger Clinic and Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer. 2007 Sep 15;110(6):1396-403.</citation>
    <PMID>17674351</PMID>
  </results_reference>
  <results_reference>
    <citation>Jatoi A, Dakhil SR, Kugler JW, et al.: A placebo-controlled trial of etanercept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North Central Cancer Treatment Group (NCCTG) trial N00C1. [Abstract] J Clin Oncol 24 (Suppl 18): A-8534, 476s, 2006.</citation>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Aminah Jatoi, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>anorexia</keyword>
  <keyword>cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

